Knockdown of nuclear factor erythroid 2-related factor 2 by lentivirus induces differentiation of glioma stem-like
Jianhong Zhu1, Handong Wang1, Youwu Fan1
1Department of Neurosurgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, P.R. China.
Abstract:
Glioma stem cells (GSCs) are key in the progression and recurrence of glioblastoma. Inducing the differentiation of GSCs is an important therapeutic target for glioblastoma. Nuclear factor erythroid 2-related factor 2 (Nrf2) has been reported to be important in maintaining the stem cell status of GSCs; however, its association with differentiation has not been studied. Herein, we knocked down Nrf2 from GSCs to investigate the role of Nrf2 in the differentiation of GSCs. First, Nrf2 expression was observed at different stages of differentiation; then, Nrf2 was knocked down and the association of Nrf2 with differentiation degree was observed in vitro. Finally, GSCs were planted in nude mice to study the association of Nrf2 with differentiation in vivo. The expression of Nrf2 decreased with the differentiation process. Following Nrf2 knockdown, the proportion of sphere-like colonies decreased and the dendritic cells in spheres increased; the expression of Nrf2 significantly decreased while the expression of differentiation marker glial fibrillary acidic protein (GFAP) and βIII-tubulin increased both at the protein and the gene level. In the xenografts of nude mice, the differentiation of tumor cells was improved. These results suggest that Nrf2 is a key factor inhibiting the differentiation of GSCs, and knockdown of Nrf2 may promote the differentiation process, providing a therapy target for GSCs.
Insights
Nuclear factor erythroid 2-related factor 2 (Nrf2) inhibits glioma stem cell differentiation. Knocking down Nrf2 promotes glioma stem cell differentiation, offering a potential therapeutic strategy for glioblastoma treatment.
Area of Science:
- Neuro-oncology
- Cancer Stem Cell Biology
- Molecular Therapeutics
Background:
- Glioma stem cells (GSCs) drive glioblastoma (GBM) progression and recurrence.
- Targeting GSC differentiation is a promising therapeutic strategy for GBM.
- The role of Nuclear factor erythroid 2-related factor 2 (Nrf2) in GSC differentiation remains unexplored.
Purpose of the Study:
- To investigate the role of Nrf2 in the differentiation of GSCs.
- To determine if Nrf2 inhibition can promote GSC differentiation.
Main Methods:
- Nrf2 expression analysis during GSC differentiation.
- Nrf2 knockdown in GSCs followed by in vitro differentiation assays.
- In vivo studies using nude mouse xenografts to assess Nrf2's role in GSC differentiation.
Main Results:
- Nrf2 expression inversely correlated with GSC differentiation.
- Nrf2 knockdown reduced sphere formation and increased dendritic cell markers.
- Nrf2 knockdown upregulated differentiation markers (GFAP, βIII-tubulin) at protein and gene levels.
- Tumor cell differentiation was enhanced in vivo following Nrf2 knockdown.
Conclusions:
- Nrf2 acts as a key inhibitor of GSC differentiation.
- Nrf2 knockdown promotes GSC differentiation, presenting a potential therapeutic target for glioblastoma.
More Related Videos
09:24Combined Conditional Knockdown and Adapted Sphere Formation Assay to Study a Stemness-Associated Gene of Patient-derived Gastric Cancer Stem Cells
Published on: May 9, 2020
09:09Laser Capture Microdissection of Glioma Subregions for Spatial and Molecular Characterization of Intratumoral Heterogeneity, Oncostreams, and Invasion
Published on: April 12, 2020
